AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01511159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose by inhalation. Progression to open-label trial part will be based on safety data
Study NCT01511159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
Study NCT01511159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
Study NCT01511159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin human
Description: Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
Study NCT01143363 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: resting - control
Study NCT01143363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Study NCT01143363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity intermittent training
Study NCT01511159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin human
Description: Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
Study NCT01511159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
Study NCT03307694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
Study NCT03307694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elasticity imaging
Description: Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue.
Study NCT03307694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-angle compound shear wave elasticity imaging
Description: The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
Study NCT03329612 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Serial inflations and deflations as detailed in the arm/group descriptions.
Study NCT03329612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Serial inflations and deflations as detailed in the arm/group descriptions.
Study NCT03869970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REST
Description: The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals
Study NCT03869970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVITY
Description: ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.
Study NCT03869970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHEALTH
Description: mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
Study NCT01143363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short sprint
Study NCT04160286 — intervention group
Intervention type: OTHER
Intervention: Electroconvulsive therapy
Description: Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)
Study NCT02040350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pralidoxime
Description: Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
Study NCT02040350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pralidoxime
Description: Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
Study NCT01694121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEN Count
Description: The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
Study NCT01694121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: general health intervention for men, not inclusive of HIV or relationship health
Study NCT01877486 — intervention group
Intervention type: PROCEDURE
Intervention: Ablation
Description: Pulmonary vein isolation following dofetilide
Study NCT00980512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: 16 weeks of parent training led by trained group facilitator
Study NCT02113267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
Study NCT02113267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
Study NCT04402736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The modified Barthel Index-based rehabilitation nursing program
Description: The intervention with the program based on the MBI classified function of patients into five levels, with every 20 points as a level, Each level corresponds to different training items. Training items included self-care training and training in transfer activities, sitting balance, walking, and sit-to-stand, etc. Each training session lasting at least 30 minutes, two sessions per day, for seven continuous days. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
Study NCT04402736 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Patients in the control group received clinical usual care including the activities of daily living assessment, early mobilization guide and health education. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
Study NCT02130557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
Study NCT02130557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator.
Study NCT01357694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapeutic contacts
Description: psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
Study NCT03160521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 75 mg
Description: Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Study NCT03160521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 100 mg
Description: Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Study NCT03160521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Risperidone ISM
Description: Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Study NCT02134262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide or Bendamustine
Description: Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.
Study NCT02134262 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level -1
Description: CD19-CAR-T \[1 x 10\^5 cells/kg x 1 day and 2 x 10\^5 cells/kg x 1 day Intravenous (IV)\] are administered.
Study NCT02134262 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 1
Description: CD19-CAR-T \[1/3 x 10\^6 cells/kg x 1 day and 2/3 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
Study NCT02134262 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 2
Description: CD19-CAR-T \[1 x 10\^6 cells/kg x 1 day and 2 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
Study NCT02134262 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 3
Description: CD19-CAR-T \[1/3 x 10\^7 cells/kg x 1 day and 2/3 x 10\^7 cells/kg x 1 day Intravenous (IV)\] are administered.
Study NCT03878381 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Skin Care Cream
Description: The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
Study NCT03878381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be a formula with no active ingredients
Study NCT01700998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Study NCT01700998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04190381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FR-Mask
Description: The investigational medical product of this study is a biomedical repair mask, FR-MASK, acting like moisturizing lotion applied on breasts.~The FR-Mask is applied to users' radiation-irritated breast skin for 15 to 20 minutes every 3 days.
Study NCT01997632 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)
Description: a single dose m-IPV2 HD (study vaccine), 0,5ml
Study NCT02139878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wild blueberry juice
Study NCT02139878 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo wild blueberry juice
Study NCT04328753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Super Oxide water
Description: Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
Study NCT04328753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
Study NCT04328753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: act as a negative control in this study
Study NCT02140008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of I-gel
Description: After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
Study NCT02140008 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of air-Q
Description: After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
Study NCT02030717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: klonidin
Description: spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
Study NCT01111825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 28 day treatment cycle Phase 1~* Weekly intravenously (IV) on days 1, 8, 15, and 22~* Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~* Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~* HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22
Study NCT01111825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 28 day treatment cycle~• 240 mg orally daily
Study NCT04618783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
Description: Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Study NCT04618783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
Description: Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Study NCT04618783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
Description: Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Study NCT04618783 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three doses of control wIPV, vaccinated within one-month interval between doses
Description: Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Study NCT04618783 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three doses of control sIPV, vaccinated within one-month interval between doses
Description: Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Study NCT01997632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).
Description: a single 0.5 ml dose Imovax Polio (control vaccine)
Study NCT01152242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoglycemic Clamp
Description: Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
Study NCT06046196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate SR
Description: Sarpogrelate SR 300mg, once a daily, for 24weeks
Study NCT04267029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TADPOL battery (deep clinicolaboratory profile)
Description: profile dimensions:~* hemolytic~* allergic~* cardiorenal~* inflammatory~* leukoagglutinating~* exploratory bioarchive
Study NCT04385303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint
Description: One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle
Study NCT04385303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
Study NCT06046196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpogrelate
Description: Sarpogrelate 100mg, 3 times a day, for 24weeks
Study NCT03875066 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stepping training without feedback
Description: Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
Study NCT01442688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin + MMX placebo
Description: MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
Study NCT01442688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin + MMX mesalazine/mesalamine
Description: MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
Study NCT04258462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV
Study NCT04258462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04258462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C,15N2-urea
Description: Given IV
Study NCT03357653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan group
Description: Losartan 50 mg daily
Study NCT03357653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 1 pill daily
Study NCT02030717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural anesthesia
Description: epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
Study NCT04177953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin AUC 5
Description: chemotherapy iv
Study NCT04177953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5
Description: chemotherapy iv
Study NCT04177953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 75 mg/m2
Description: chemotherapy iv
Study NCT04177953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2
Description: chemotherapy iv
Study NCT04177953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed 500 mg/m2
Description: chemotherapy iv
Study NCT03875066 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stepping training with feedback
Description: Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
Study NCT04177953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2
Description: chemotherapy iv
Study NCT04177953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Human monoclonal antibody